Implications Of 2seventy’s CAR-T Trial Pause Uncertain

14 Jun 2023

Seattle Children’s, the biotech’s partner, halted a Phase I acute myeloid leukemia cell therapy trial due to a patient death following the start of a second dosing level cohort.

An investigation into the study drug’s role is just getting started, but a Phase I clinical trial of 2seventy Bio, Inc.’s SC-DARIC33 chimeric antigen receptor T-cell (CAR-T) therapy candidate in acute myeloid leukemia was paused after a patient died. The bluebird bio spinout said on 14 June that its partner Seattle Children's Hospital & Medical Center placed the study on hold following a patient death in the second dose level of three scheduled doses to be tested in the PLAT-08 trial.

PLAT-08 is the first in-human trial of 2seventy’s Dimerizing Agent Regulated Immunoreceptor Complex (DARIC) technology, which it has said offers...